Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2025 | Making alloSCT safer for patients: the value of graft engineering techniques

Rawan Faramand • 4 Sep 2025
SOHO 2025
General ORCA-T

Rawan Faramand, MD, Moffitt Cancer Center, Tampa, FL, highlights advances made in allogeneic stem cell transplantation (alloSCT) for patients with hematological malignancies, emphasizing the value of using graft engineering techniques to make alloSCT safer. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rawan Faramand

Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies 1:45
Precision-T trial: Orca-T vs tacrolimus-methotrexate for GvHD prevention in hematologic malignancies
Rawan Faramand • 4 Sep 2025

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Expanding CAR-T therapy to smaller centers to meet rising demand 1:28
Expanding CAR-T therapy to smaller centers to meet rising demand
Sunil Gupta • 5 Dec 2025
Replacing standard FISH panels with WGS in multiple myeloma 1:49
Replacing standard FISH panels with WGS in multiple myeloma
Francesco Maura • 8 Dec 2025
Results of a survey investigating fertility and outcomes after CAR T-cell therapy 1:13
Results of a survey investigating fertility and outcomes after CAR T-cell therapy
Florent Malard • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals